SCHEMBL3634948

SCHEMBL3634948

CC(C)(C(N)=O)N1CCCC1

nearest known ligand 0.36

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ATM Q13315 1/20 0.34
PARP1 P09874 2/20 0.33
HSD11B1 P28845 1/20 0.33
HSD11B2 P80365 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ALDH1A1 P00352 2/20 0.32
CYP2B6 P20813 1/20 0.31
SIGMAR1 Q99720 2/20 0.31
SYK P43405 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3635465 0.97 L3MBTL1 (0.37) LMNASMN1; SMN2ATMPARP1HSD11B1
Hydrochloric Acid SCHEMBL9698155 0.95 L3MBTL1 (0.35) LMNASMN1; SMN2ATMPARP1HSD11B1
SCHEMBL23278023 0.82 ATM (0.42) LMNASMN1; SMN2ATMSIGMAR1
SCHEMBL4404464 0.80 CYP1A2 (0.41) LMNASMN1; SMN2ATMALDH1A1SIGMAR1
SCHEMBL28321078 0.80 ATM (0.32) SMN1; SMN2ATMPARP1L3MBTL1ALDH1A1
SCHEMBL4104348 0.80 ATM (0.36) ATMPARP1L3MBTL1ALDH1A1
SCHEMBL18123290 0.78 LMNA (0.37) LMNASMN1; SMN2ATM
SCHEMBL1088468 0.78 SIGMAR1 (0.37) LMNASMN1; SMN2ATMSIGMAR1
SCHEMBL3314582 0.78 LMNA (0.37) LMNASMN1; SMN2ATM
SCHEMBL2862694 0.78 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024145483-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME HTG MOLECULAR DIAGNOSTICS, INC. (US) 2024-07-04 WO claimed
CN-117343028-A Ionic liquid electrolyte with wide window, and preparation method and application thereof 辽宁大学 2024-01-05 CN claimed
CN-117343028-A Ionic liquid electrolyte with wide window, and preparation method and application thereof 辽宁大学 2024-01-05 CN disclosed
WO-2020258893-A1 A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE HANGZHOU DAC BIOTECH CO., LTD (CN) 2020-12-30 WO disclosed
EP-2265585-B1 AMINE AND ETHER COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2014-09-17 EP disclosed
US-20120142685-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-06-07 US disclosed
EP-2144909-A1 [2, 6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS Novartis Ag (CH) 2010-01-20 EP disclosed
WO-2008122615-A1 [2, 6] NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142685-A1 ORGANIC COMPOUNDS MARK1, PKN1, MARK2 LMNA 2683/4885SMN1; SMN2 3821/4885ATM 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.